{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:05:02Z","timestamp":1763535902410},"reference-count":0,"publisher":"Codon Publications","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["aei"],"abstract":"<jats:p>Background: Asthma is characterized by a chronic airway inflammation, usually sustained by type 2 immunity. Bronchial and peripheral eosinophilia are biomarkers for type 2 asthma. Biologicals are the most effective treatment for severe asthma at present. Mepolizumab is an antagonist of interleukin-5 (IL-5), the most relevant cytokine involved in eosinophilia.Objective: This case report evaluated the effectiveness of mepolizumab in two girls with severe eosinophilic non-allergic asthma.Materials and methods: Two female children with severe eosinophilic nonallergic asthma were treated with mepolizumab for two years. Clinical findings, lung function, peripheral eosinophils, asthma control, and bronchial endoscopy were performed.Results: Biologicals reduced the eosinophilia, asthma exacerbations, and improved lung function in both patients. The treatment was also safe and well-tolerated.Conclusion: Mepolizumab represents an effective therapeutic option in the management of severe pediatric asthma.\n\u00a0<\/jats:p>","DOI":"10.15586\/aei.v49i5.466","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:42:19Z","timestamp":1630582939000},"page":"113-116","source":"Crossref","is-referenced-by-count":4,"title":["Steroid-sparing effect of mepolizumab in children with severe eosinophilic nonallergic asthma"],"prefix":"10.15586","volume":"49","author":[{"given":"Maria Angela","family":"Tosca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Girosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliviero","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Ciprandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6228","published-online":{"date-parts":[[2021,9,1]]},"container-title":["Allergologia et Immunopathologia"],"original-title":[],"link":[{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/466\/640","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/466\/641","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/466\/642","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/download\/466\/640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T11:42:32Z","timestamp":1630669352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.all-imm.com\/index.php\/aei\/article\/view\/466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.15586\/aei.v49i5.466","relation":{},"ISSN":["0301-0546"],"issn-type":[{"value":"0301-0546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}